Use and "real-world" effectiveness of smoking cessation methods in patients with chronic obstructive pulmonary disease (RESPIRO)

Use and "real-world" effectiveness of smoking cessation methods in patients with chronic obstructive pulmonary disease (RESPIRO) - RESPIRO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015450

Enrollment

2000

Registered

2018-09-05

Start date

2018-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44.8 J44.9 F17.2

Interventions

Group 1: Within the proposed cross-sectional study, we aim to collect baseline questionnaire data of 2,000 tobacco smokers and recent ex-smokers (<12 months abstinence) with COPD from 25 pulmonary pra

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Current tobacco smokers (daily or occasionally) or recent ex-smoker (<12 months) with confirmed diagnosis of COPD: a. J44.8 Other specified chronic obstructive pulmonary disease, including chronic bronchitis: asthmatic (obstructive) – emphysematous – obstructive, b. J44.9 Chronic obstructive pulmonary disease, unspecified

Exclusion criteria

Exclusion criteria: 1) Other severe or chronic pulmonary diagnosis, e.g. tuberculosis or bronchial carcinoma; 2) Moderate or severe cognitive impairment or low literacy

Design outcomes

Primary

Measure	Time frame
1) Prevalence rates of use of evidence-based (e.g., nicotine replacement therapy, bupropion, varenicline, behavioural support) and non-evidence based (e.g. hypnosis, acupuncture, e-cigarettes) smoking cessation methods in COPD patients during their most recent quit attempt. 2) The real-world effectiveness of these smoking cessation methods with cross-sectional data, adjusted for potential confounders (in particular nicotine dependence). These parameters will be collected by paper-and-pencil baseline questionnaire.	—

Measure

Time frame

1) Prevalence rates of use of evidence-based (e.g., nicotine replacement therapy, bupropion, varenicline, behavioural support) and non-evidence based (e.g. hypnosis, acupuncture, e-cigarettes) smoking cessation methods in COPD patients during their most recent quit attempt. 2) The real-world effectiveness of these smoking cessation methods with cross-sectional data, adjusted for potential confounders (in particular nicotine dependence). These parameters will be collected by paper-and-pencil baseline questionnaire.

—

Secondary

Measure	Time frame
1) The real-world effectiveness of smoking cessation methods with longitudinal data (6-month follow-up). These parameters will be collected by paper-and-pencil follow-up survey. 2) Prevalence rates of the use of so-called "harm reduction" strategies (such as "cutting down"), rates (and duration) of smoking cessation attempts, external and internal triggers of these attempts. These parameters will be collected by paper-and-pencil baseline questionnaire together with the primary endpoints. 3) Differences in key performance indicators of smoking cessation between smokers with COPD and the general smoking population of Germany (comparison of primary and secondary outcomes of RESPIRO with data from our ongoing DEBRA study (German Study on Tobacco Use), DRKS00011322).	—

Measure

Time frame

1) The real-world effectiveness of smoking cessation methods with longitudinal data (6-month follow-up). These parameters will be collected by paper-and-pencil follow-up survey. 2) Prevalence rates of the use of so-called "harm reduction" strategies (such as "cutting down"), rates (and duration) of smoking cessation attempts, external and internal triggers of these attempts. These parameters will be collected by paper-and-pencil baseline questionnaire together with the primary endpoints. 3) Differences in key performance indicators of smoking cessation between smokers with COPD and the general smoking population of Germany (comparison of primary and secondary outcomes of RESPIRO with data from our ongoing DEBRA study (German Study on Tobacco Use), DRKS00011322).

—

Countries

Germany

Contacts

Public ContactYekaterina Pashutina

Institut für Allgemeinmedizin (ifam) Medizinische Fakultät der Heinrich Heine Universität

Respiro-Studie@med.uni-duesseldorf.de021154084245

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026